
Global R&D Pipeline
My Favorite
Hot Targets:
ITGB4
Back
Total number of drugs
6
Phase II and later clinical stages
0%
Involving companies
8
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AAA-604 | AAA-604 | Therapeutic radiopharmaceuticals | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | integrin subunit beta 3 inhibitors integrin subunit beta 4 inhibitors | Novartis AG | Novartis AG | Phase 1 | AAA-604 | detail > | ||||||||||||
| CS-5006 | CS-5006 | Antibody drug conjugate (ADC) ADC | Neoplasms | integrin subunit beta 4 inhibitors DNA topoisomerase I inhibitors | Cornerstone Pharmaceutical Co., Ltd | Cornerstone Pharmaceutical Co., Ltd | Preclinical | Preclinical | β-glucuronide Beta-葡萄糖醛酸苷 | Exatecan 依喜替康 | CS-5006 | detail > | |||||||||
| GENA-120 | GENA-120 | Antibody drug conjugate (ADC) ADC | Neoplasms | integrin subunit beta 4 inhibitors DNA topoisomerase I inhibitors | Genome & Co. | Genome & Co. | Preclinical | GENA-120 | detail > | ||||||||||||
| GENB-120 | GENB-120 | Antibody drug conjugate (ADC) ADC | Neoplasms | integrin subunit beta 4 inhibitors Tumor-associated calcium signal transducer 2 inhibitors | Genome & Co. | Genome & Co. | Preclinical | GENB-120 | detail > | ||||||||||||
| Halofuginone Hydrobromide | Halofuginone Hydrobromide | Degradable Molecular Glue | Immune System Diseases Infectious Diseases Skin and Musculoskeletal Diseases | Collagen inhibitors Aminoacyl-tRNA synthetase inhibitors integrin subunit beta 4 inhibitors Angiogenesis inhibitors | Akashi Therapeutics Inc | National Institute of Malaria ResearchICGEB New DelhiHunan University of Chinese MedicineAcademy of Scientific & Innovative Research | Preclinical | Preclinical | United States | Halofuginone Hydrobromide | detail > | ||||||||||
| WO2024208354 | WO2024208354 | Antibody Fragment-Drug Conjugates (FDCs) | Neoplasms | Cornerstone Pharmaceutical Co., Ltd | Cornerstone Pharmaceutical Co., Ltd | Discovery | WO2024208354 | detail > |
Total 6 data
1


